Baillie Gifford & CO Bio N Tech Se Transaction History
Baillie Gifford & CO
- $128 Billion
- Q3 2025
A detailed history of Baillie Gifford & CO transactions in Bio N Tech Se stock. As of the latest transaction made, Baillie Gifford & CO holds 7,879,359 shares of BNTX stock, worth $825 Million. This represents 0.61% of its overall portfolio holdings.
Number of Shares
7,879,359
              Previous 8,038,872
              
        
           1.98%
        
      
          
        Holding current value
$825 Million
            Previous $856 Million
            
        
           9.21%
        
      
          
        % of portfolio
0.61%
            Previous 0.67%
          
        Shares
	  19 transactions
	
  Others Institutions Holding BNTX
# of Institutions
318Shares Held
40.8MCall Options Held
1.37MPut Options Held
1.52M- 
    
      Flossbach Von Storch Ag Cologne, 2M4.23MShares$443 Million1.88% of portfolio
- 
    
      Primecap Management CO Pasadena, CA4MShares$419 Million0.35% of portfolio
- 
    
      T. Rowe Price Investment Management, Inc. Baltimore, MD3.6MShares$377 Million0.24% of portfolio
- 
    
      Black Rock Inc. New York, NY1.9MShares$198 Million0.0% of portfolio
- 
    
      Temasek Holdings (Private) LTD Singapore, U01.51MShares$158 Million0.79% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $25.4B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...